NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition
Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were "key methodological limitations" to the study.
Using Ozempic Or Wegovy Could Raise Risk For Rare Form Of Blindness, Study Suggests
People who use Ozempic or Wegovy for treating obesity or Type 2 diabetes may have an increased risk of developing a rare form of blindness, according to a study published Wednesday in the journal JAMA Network, which Novo Nordisk has criticized for being insufficient.
Wegovy, Ozempic linked with sight-threatening eye disorder in study
Patients using Novo Nordisk's wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from a study published on Wednesday.
Why Novo Nordisk Stock Is Slipping Today
A USA Today op-ed from President Joe Biden and Sen. Bernie Sanders criticized Novo Nordisk.
How To Pick Top Pharma Stocks: Novo Nordisk And More
This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of the investment attractiveness of this or that company. The rest of the article will contain an analysis of Novo Nordisk, which is a leader in the fast-growing anti-obesity medicines market.
Novo Nordisk must cut prices of weight-loss drug, Biden says in USA Today piece
U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk to cut prices of its Ozempic and Wegovy drugs for weight loss and diabetes, in an opinion piece by them published in USA Today on Tuesday.
Novo Nordisk steps up ad spend to keep the weight-loss crown
Novo Nordisk (NYSE:NVO) appears to be taking a no-holds-barred approach to becoming the number one weight-loss drug in the US after it emerged that an ad for one of its key products was viewed nearly 2 billion times between June 3 and June 25, making it the third most-watched commercial during that period. The Wall Street Journal, citing iSpot.tv, reported the Wegovy ad, titled "Discover the Power", was shown 6,271 times and cost an estimated $42 million in national airtime.
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Novo Nordisk's flagship obesity care treatment, Wegovy, recently received approval in China. Obesity is a big medical issue in China, estimated to affect hundreds of millions of people.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
Novo Nordisk makes impairment loss of $816 mln in Q2
Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.
